

United States Patent and Trademark Office (1)

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/532,384	04/21/2005	Yuri V. Korshak	05-330-A	1758
20306 . 7590 01/22/2008 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE			EXAMINER	
			ELLIS, SUEZU Y	
32ND FLOOR CHICAGO, IL 60606		ART UNIT	PAPER ŅUMBER	
			1615	
			MAIL DATE	DELIVERY MODE
		•	01/22/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/532,384	KORSHAK ET AL.				
Office Action Summary	Examiner	Art Unit				
	Suezu Ellis	1615				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
Responsive to communication(s) filed on 4/21/6 2a) This action is FINAL . 2b) This 3) Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. ce except for formal matters, pro					
Disposition of Claims						
4) Claim(s) 1-17 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 1-17 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or						
Application Papers		•				
9) ☐ The specification is objected to by the Examiner 10) ☑ The drawing(s) filed on 21 April 2005 is/are: a) Applicant may not request that any objection to the o Replacement drawing sheet(s) including the correction 11) ☐ The oath or declaration is objected to by the Examiner	☑ accepted or b)☐ objected to be frawing(s) be held in abeyance. See on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 4/21/05.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	te				

10/532,384 Art Unit: 1615

DETAILED ACTION

Information Disclosure Statement

The information disclosure statement (IDS) submitted on April 21, 2005 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gayser, Jr. et al. (US 6,660,302) in view of Gulian et al. (US 2003/0072731).

With respect to claims 1-17, Gayser et al. discloses a capsule for oral delivery of a composition comprising gum acacia (equivalent to gum arabic), a water-soluble polymer (hydroxypropylmethylcellulose) and a plasticizer (polyethylene glycol) (col. 3, line 24; col. 2, lines 23-27). Gayser et al. further discloses the capsules contain pharmaceuticals (col. 2, lines 19-22). Gayser et al. further discloses dissolving the composition in water thereby forming an aqueous solution (col. 7, lines 5-26). Gayser et al. discloses the gum acacia being in the range of 5-90%, therefore applicant's claimed range of 60-95% can be attained. Gayser et al. further discloses the exact proportions

Application/Control Number:

10/532.384

Art Unit: 1615

of the gum acacia and hydroxypropylmethylcellulose are not critical. It would have been obvious to one of ordinary skill in the art to modify the range of the content of gum acacia in order to attain desired physical properties of the capsule coatings. Further, it has been held that where the general conditions of a claim are discloses in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. In re Aller, 105 USPQ 233.

Gayser et al. further fails to expressly disclose the inclusion of a hydrocolloid. Gulian et al. discloses a film-forming composition for manufacturing capsules comprising a cellulose ether (hydroxypropylmethylcellulose) and thickeners (carageenan) [0024]. Gulian et al. further discloses the thickener can be a combination of kappa carrageenan and gum Arabic [0032]. It would have been obvious to one of ordinary skill in the art to include kappa-carrageenan in the composition as a means of inducing gelation of the water-soluble polymer for the predictable result of forming hard capsules.

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Gennadios (US 6,214,376) discloses a formulation of oral delivery capsules comprising kappa-carrageenan (composition 9).

Telephone/Fax Information

10/532,384

Art Unit: 1615

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suezu Ellis whose telephone number is (571) 272-2868. The examiner can normally be reached on 8:30am-5pm (Monday-Friday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

SE

MTCHAEL P. WOODWARD SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600